Confidential Treatment Requested by Vallon Pharmaceuticals, Inc. Pursuant to 17 C.F.R. Section 200.83 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM...License Agreement • November 16th, 2020 • Vallon Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
LICENSOR is active in the development and commercialization of pharmaceutical products for the treatment of central nervous system disorders and owns or controls certain intellectual property rights, secret processes, know-how and technical information relating to the manufacture, formulation and use of “ADAIR” (Abuse Deterrent Amphetamine Immediate Release) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Narcolepsy.
